Table 1—

Oral antidiabetes drug use in seven case subjects with lactic acidosis

Case no.Age (years)/sexUse of oral antidiabetes drugsApproximate duration of metformin use prior to diagnosis (months)Time between last metformin prescription and diagnosis (days)Relevant comorbidities and outcome (died or survived)
183/femaleMetformin, glibenclamide5721Acute renal failure, acute heart failure (hypertensive heart disease) (died)
263/femaleMetformin, gliclazide1113Acute seizure, stable hypertensive heart disease, nonexacerbated chronic obstructive pulmonary disease (survived)
370/femaleGliclazideUrosepsis (survived)
474/maleMetformin, gliclazide11106*Stable hypertensive heart disease, nonexacerbated chronic obstructive pulmonary disease (survived)
582/femaleMetformin2952Acute gastroenteritis with hypovolemia (died)
642/femaleMetformin, pioglitazone827Stable hypertensive heart disease, liver cirrhosis (survived)
770/maleMetformin, gliclazide3236Acute heart failure (hypertensive heart disease) (survived)
  • *

    * Patient no. 4 was classified as a “past metformin user” because the tablet supply of the last metformin prescription prior to the index date was likely to not last up to or beyond the index date (for details, see text).